Equities

Talis Biomedical Corp

TLIS:PKC

Talis Biomedical Corp

Actions
  • Price (USD)1.85
  • Today's Change0.05 / 2.78%
  • Shares traded285.00
  • 1 Year change-65.15%
  • Beta1.5743
Data delayed at least 15 minutes, as of Oct 18 2024 20:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Talis Biomedical Corporation is a molecular diagnostic company. The Company is focused on advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.

  • Revenue in USD (TTM)408.00k
  • Net income in USD-51.03m
  • Incorporated2013
  • Employees99.00
  • Location
    Talis Biomedical Corp1375 West Fulton Market, Suite 700CHICAGO 60607United StatesUSA
  • Phone+1 (650) 433-3000
  • Fax+1 (302) 636-5454
  • Websitehttps://talisbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Petros Pharmaceuticals Inc4.12m-20.64m3.07m21.00--0.3687--0.746-6.54-6.541.000.9880.15290.67951.89196,223.30-26.18-32.43-39.25-68.0570.2162.04-171.23-201.701.26--0.4539---2.83-16.1531.06------
Windtree Therapeutics Inc0.00-11.38m3.36m15.00--0.1547-----0.7463-0.74630.0017.650.00----0.00-32.86-44.51-40.15-48.38-------94,533.34----0.1612------48.25------
Talis Biomedical Corp408.00k-51.03m3.37m99.00--0.0693--8.26-28.02-28.020.22426.690.0042--1.534,121.21-52.13-68.18-57.23-74.2295.10---12,506.37-1,615.96----0.00---55.65-2.2445.13---1.83--
Theriva Biologics Inc0.00-22.27m3.39m21.00--1.29-----1.25-1.250.001.230.00----0.00-41.30-36.95-48.49-40.16------------0.0056------8.37--95.91--
InMed Pharmaceuticals Inc4.60m-7.68m3.39m13.00--0.2321--0.7367-1.33-1.330.60271.030.35462.4414.99---59.20-92.09-69.92-113.1723.94---166.94-543.293.78--0.00--11.18--3.42---19.10--
Therapeutic Solutions International Inc91.38k-2.00m3.42m3.00--2.48--37.41-0.0005-0.00050.000020.00030.02521.295.2430,460.00-63.67-162.32-153.29--65.1867.79-2,530.31-2,391.850.3883-6.940.3164---52.1395.3543.11------
Oragenics Inc7.47k-19.52m3.43m5.00------459.80-6.99-6.990.00230.23770.0013----1,494.00-349.31-97.60-451.26-106.24-----261,261.60-36,169.75----0.00---71.37---44.56--51.64--
Revelation Biosciences Inc0.00-15.90m3.46m9.00--1.33-----29.75-29.750.000.69390.00----0.00-112.35---253.32--------------0.00------98.89------
Helix BioMedix, Inc.2.07m-2.58m3.51m8.00--2.25--1.70-15.60-15.6012.486.950.80471.874.55258,238.80-100.64-146.31-120.73-173.5768.9630.80-125.06-527.121.69-14.570.00--122.0792.8067.73---29.08--
Alaunos Therapeutics Inc7.00k-19.13m3.62m1.00--0.9597--516.98-11.95-11.950.00442.360.0004--1.757,000.00-117.34-74.83-143.58-89.57-----273,271.40-10,508.06----0.00---99.83-49.086.86---15.56--
ENDRA Life Sciences Inc0.00-9.57m3.69m21.00--0.0328-----45.63-45.630.006.210.00----0.00-97.17-132.00-117.34-157.28------------0.00------23.67---19.46--
Data as of Oct 18 2024. Currency figures normalised to Talis Biomedical Corp's reporting currency: US Dollar USD

Institutional shareholders

43.56%Per cent of shares held by top holders
HolderShares% Held
Baker Bros. Advisors LPas of 08 Oct 2024508.32k27.89%
DME Capital Management LPas of 30 Jun 2024149.05k8.18%
The Vanguard Group, Inc.as of 31 Aug 202451.28k2.81%
BML Capital Management LLCas of 30 Jun 202442.74k2.35%
Prelude Capital Management LLCas of 30 Jun 202414.93k0.82%
Geode Capital Management LLCas of 31 Aug 202413.66k0.75%
G1 Execution Services LLCas of 30 Jun 202411.61k0.64%
BlackRock Advisors LLCas of 30 Aug 20241.44k0.08%
Tower Research Capital LLCas of 30 Jun 2024877.000.05%
Steward Partners Investment Advisory LLCas of 30 Jun 2024147.000.01%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.